Document is current
Any future updates will be listed below
-
Authors
Murray, Lindsey T. https://orcid.org/0000-0002-9168-2179
Yin, Yin
Phillips, Dawn
Coats, Julie
Tran, Ha
Dashiell-Aje, Ebony
Rizzo, Marco
Parker, Samantha
,
-
Funding
Funding for this research was provided by:
Biogen
Critical Path Institute
- License Information
-
More Information
Article History
Received: 29 July 2025
Accepted: 22 September 2025
First Online: 21 November 2025
Declarations
:
: Samantha Parker is Vice Chair for the International Rare Diseases Research Consortium and was an employee of Innoskel during the development of this manuscript. Yin Yin was an employee of Biogen during the development of this manuscript, and has subsequently retired. Dawn Phillips was an employee of REGENXBIO Inc during the development of this manuscript. Julie Coats was an employee of Astellas Pharma Inc during the development of this manuscript and received financial and short- and long-term rewards. She is currently an employee of Avidity Biosciences. Ha Tran is an employee of Astellas Pharma Inc and received financial and short- and long-term rewards. Ebony Dashiell-Aje is an employee of BioMarin Pharmaceutical Inc. Marco Rizzo is an employee of Biogen and owns Biogen stock. Lindsey Murray has no competing interests. Representatives of the pharma members of the Rare Disease COA Consortium had the opportunity for a courtesy review and approval of the article.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
